Patents by Inventor Sidney Altman
Sidney Altman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9801948Abstract: Antimicrobial compositions including a cell penetrating peptide (CPP) having the amino acid sequence Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Gly-Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Arg (SEQ ID NO:1) or variant thereof are disclosed. The CPP, which itself has antimicrobial properties, can be advantageously combined with or conjugated to a cargo to increase the delivery, efficacy, or combinations thereof, of the cargo into cells. In preferred embodiments, the CPP is combined with or conjugated to a functional nucleic acid, such as an external guide sequence (EGS) which can target and reduce expression of essential microbial genes or genes than impart resistance to antimicrobial drugs. Methods of using the compositions alone or in combination with traditional antimicrobial drugs to treat infections are also disclosed.Type: GrantFiled: September 21, 2012Date of Patent: October 31, 2017Assignee: Yale UniversityInventors: Sidney Altman, Alfred Bothwell, Choukri Mamoum
-
Publication number: 20140220086Abstract: Antimicrobial compositions including a cell penetrating peptide (CPP) having the amino acid sequence Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Gly-Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Arg (SEQ ID NO:1) or variant thereof are disclosed. The CPP, which itself has antimicrobial properties, can be advantageously combined with or conjugated to a cargo to increase the delivery, efficacy, or combinations thereof, of the cargo into cells. In preferred embodiments, the CPP is combined with or conjugated to a functional nucleic acid, such as an external guide sequence (EGS) which can target and reduce expression of essential microbial genes or genes than impart resistance to antimicrobial drugs. Methods of using the compositions alone or in combination with traditional antimicrobial drugs to treat infections are also disclosed.Type: ApplicationFiled: September 21, 2012Publication date: August 7, 2014Inventors: Sidney Altman, Alfred Bothwell, Choukri Mamoum
-
Patent number: 5976874Abstract: External guide sequences ("EGS") can be used to promote RNAase P-mediated cleavage of RNA transcribed from plasmids and other genetic elements which confer drug resistance on bacterial cells. Such cleavage can render the bacteria drug sensitive. In a preferred embodiment, a vector encoding an EGS is administered to an animal or human harboring antibiotic resistant bacterial cells such that the EGS is expressed in the bacterial cells, the EGS promotes RNAase P-mediated cleavage of RNA involved in conferring antibiotic resistance to the cells, and the cells are rendered antibiotic sensitive. A preferred form of administration is via inoculation of the animal or human with cells containing genes for appropriate EGSs on promiscuous plasmids. These plasmids will spread quickly through the antibiotic-resistant population of bacterial cells, thereby making the cells susceptible to antibiotic therapy.Type: GrantFiled: August 15, 1997Date of Patent: November 2, 1999Assignee: Yale UniversityInventors: Sidney Altman, Cecilia Guerrier-Takada
-
Patent number: 5869248Abstract: It has been discovered that any RNA can be targeted for cleavage by RNase P from prokaryotic or eukaryotic cells using a suitably designed oligonucleotide ("external guide sequence", or EGS) to form a hybrid with the target RNA, thereby creating a substrate for cleavage by RNase P in vitro. The EGS hydrogen bonds to the targeted RNA to form a partial tRNA like structure including the aminoacyl acceptor stem, the T stem and loop, and part of the D stem. An EGS can be modified both by changes in sequence and by chemical modifications to the nucleotides. The EGS can be a separate molecule or can be combined with an RNase P catalytic RNA sequence to form a single oligonucleotide molecule ("RNase P internal guide sequence" or RIGS). Methods are also disclosed to randomly select and to express a suitable EGS or RIGS in vivo to make a selected RNA a target for cleavage by a host cell RNase P or introduced RIGS, thus preventing expression of the function of the target RNA.Type: GrantFiled: November 6, 1996Date of Patent: February 9, 1999Assignee: Yale UniversityInventors: Yan Yuan, Cecilia Guerrier-Takada, Sidney Altman, Fenyong Liu
-
Patent number: 5728521Abstract: It has been discovered that any RNA can be targeted for cleavage by RNAase P from eukaryotic cells, for example, human RNAase P, using a suitably designed oligoribonucleotide ("external guide sequence", or EGS) to form a hybrid with the target RNA, thereby creating a substrate for cleavage by RNAase P in vitro. The EGS hydrogen bonds to the targeted RNA to form a partial tRNA like structure including the aminoacyl acceptor stem, the T stem and loop, and part of the D stem. The most efficient EGS with human RNAase P is the EGS in which the anticodon stem and loop was deleted. Modifications can also be made within the T-loop. Methods are also disclosed to randomly select and to express a suitable EGS in vivo to make a selected RNA a target for cleavage by the host cell RNAase P, thus preventing expression of the function of the target RNA. The methods and compositions should be useful to prevent the expression of disease-causing genes in vivo.Type: GrantFiled: March 18, 1994Date of Patent: March 17, 1998Assignee: Yale UniversityInventors: Yan Yuan, Cecilia Guerrier-Takada, Sidney Altman, Fenyong Liu
-
Patent number: 5624824Abstract: It has been discovered that any RNA can be targeted for cleavage by RNAase P from eukaryotic cells, for example, human RNAase P, using a suitably designed oligoribonucleotide ("external guide sequence", or EGS) to form a hybrid with the target RNA, thereby creating a substrate for cleavage by RNAase P in vitro. The EGS hydrogen bonds to the targeted RNA to form a partial tRNA like structure including the aminoacyl acceptor stem, the T stem and loop, and part of the D stem. The most efficient EGS with human RNAase P is the EGS in which the anticodon stem and loop was deleted. Modifications can also be made within the T-loop. Methods are also disclosed to randomly select and to express a suitable EGS in vivo to make a selected RNA a target for cleavage by the host cell RNAase P, thus preventing expression of the function of the target RNA. The methods and compositions should be useful to prevent the expression of disease-causing genes in vivo.Type: GrantFiled: March 7, 1994Date of Patent: April 29, 1997Assignee: Yale UniversityInventors: Yan Yuan, Cecilia Guerrier-Takada, Sidney Altman, Fenyong Liu
-
Patent number: 5168053Abstract: It has been discovered that it is possible to target any RNA molecule for cleavage by RNase P by forming a hybrid region consisting of a short sequence of base pairs followed by a terminal 3'- NCCA sequence. In the preferred embodiment, the region is formed by addition of an external guide sequence consisting of a nucleotide sequence complementary to the targeted site which includes a 3'-NCCA, wherein the sequence hybridizes to the targeted RNA to form a short sequence of double-stranded RNA under conditions promoting cleavage of the substrate at the nucleotide at the 5' side of the base-paired region by the RNase P or catalytically active equivalent thereof. Specificity is determined by the complementary sequence. The sequence is preferably ten to fifteen nucleotides in length and may contain non-complementary nucleotides to the extent this does not interfere with formation of several base pairs followed by a NCCA at the 3' end.Type: GrantFiled: August 17, 1990Date of Patent: December 1, 1992Assignee: Yale UniversityInventors: Sidney Altman, Anthony C. Forster, Cecilia L. Guerrier-Takada
-
Patent number: 4520351Abstract: A passive personal alarm device is activated by release of a spring-loaded button switch which, when held down, opens an otherwise closed circuit. A time delay element in the circuit prevents sounding of the alarm for a predetermined period in the event of an accidental release of the actuating button. The button is released, either purposefully or inadvertently, during an attack and the alarm is sounded after expiration of the time delay. Once activated, the alarm device can be deactivated only by repositioning a number of coded switches in a pattern known only to the alarm user.Type: GrantFiled: March 8, 1982Date of Patent: May 28, 1985Inventors: Sidney Altman, Dan Kasha